-
LINK Medical Expands its Regulatory Services Team, Strengthening its IMPD & CMC Capabilities
Market news
PharmaSourcesMay 06, 2021
LINK Medical expands its regulatory services team, strengthening its IMPD & CMC capabilities.
-
New Progress in the Hair Loss Prevention Drug Market: JAK Inhibitor Baricitinib Reaches Phase 3 Clinical Primary Endpoint
Market news
PharmaSources.comMarch 26, 2021
Eli Lilly and Company and Incyte jointly announced on Mar. 3, 2021 that baricitinib, an oral JAK inhibitor, met its primary endpoint in Phase 3 clinical trial for the treatment of adult patients with severe alopecia areata (AA).
-
Da-pag-li-flo-zin is Well Tolerated in Hospitalized Patients
Market news
firstwordpharmaJune 28, 2021
DARE-19 is the first large randomized clinical trial to assess sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with and without type 2 diabetes hospitalized with COVID-19.
-
Celltrion gets priority review in Canada for Covid-19 drug regdanvimab
Market news
pharmaceutical-technologyAugust 03, 2021
Health Canada has granted priority review to Celltrion Healthcare’s experimental monoclonal antibody, regdanvimab (CT-P59), for the treatment of Covid-19.
-
AbbVie’s net revenues rise 33.9% in Q2 2021
Market news
pharmaceutical-technologyAugust 03, 2021
The full-year 2021 GAAP diluted EPS and adjusted diluted EPS guidance updated to $6.04 to $6.14 and $12.52 to $12.62, respectively.
-
Takeda and Frazier Healthcare Partners collaborate to develop clinical-stage norovirus vaccine candidate
Market news
expresspharmaAugust 03, 2021
Takeda Pharmaceutical Company Limited and Frazier Healthcare Partners have collaborated to launch HilleVax, Inc. (HilleVax), a biopharmaceutical company to develop and commercialise Takeda’s norovirus vaccine candidate.
-
India and UK to conduct clinical trials of Ashwagandha for promoting COVID-19 recovery
Market news
expresspharmaAugust 03, 2021
MoU signed between All India Institute of Ayurveda (under the Ministry of Ayush) and the UK’s London School of Hygiene and Tropical Medicine.
-
Achieving Aatmanirbharta in APIs: Are we on the right track?
Market news
expresspharmaAugust 03, 2021
As India gears up to celebrate its 75th Independence Day, self reliance in APIs remains a goal for the pharma sector. AatmaNirbharta will be crucial for the sector as it continues to protect the country from the existing and emerging health threats.
-
Glenmark inks agreement with SaNOtize to commercialise nasal spray for COVID-19 treatment in India and other Asian markets
Market news
expresspharmaAugust 03, 2021
Nitric oxide (NO) has anti-microbial properties with a direct proven effect on SARS-CoV-2.
-
Bharat Biotech’s ROTAVAC 5D receives WHO pre-qualification
Market news
expresspharmaAugust 03, 2021
Bharat Biotech has announced that the World Health Organization (WHO) has awarded pre-qualification to its rotavirus vaccine, ROTAVAC 5D.
LINK Medical expands its regulatory services team, strengthening its IMPD & CMC capabilities.
Eli Lilly and Company and Incyte jointly announced on Mar. 3, 2021 that baricitinib, an oral JAK inhibitor, met its primary endpoint in Phase 3 clinical trial for the treatment of adult patients with severe alopecia areata (AA).
DARE-19 is the first large randomized clinical trial to assess sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with and without type 2 diabetes hospitalized with COVID-19.
Health Canada has granted priority review to Celltrion Healthcare’s experimental monoclonal antibody, regdanvimab (CT-P59), for the treatment of Covid-19.
The full-year 2021 GAAP diluted EPS and adjusted diluted EPS guidance updated to $6.04 to $6.14 and $12.52 to $12.62, respectively.
Takeda Pharmaceutical Company Limited and Frazier Healthcare Partners have collaborated to launch HilleVax, Inc. (HilleVax), a biopharmaceutical company to develop and commercialise Takeda’s norovirus vaccine candidate.
MoU signed between All India Institute of Ayurveda (under the Ministry of Ayush) and the UK’s London School of Hygiene and Tropical Medicine.
As India gears up to celebrate its 75th Independence Day, self reliance in APIs remains a goal for the pharma sector. AatmaNirbharta will be crucial for the sector as it continues to protect the country from the existing and emerging health threats.
Nitric oxide (NO) has anti-microbial properties with a direct proven effect on SARS-CoV-2.
Bharat Biotech has announced that the World Health Organization (WHO) has awarded pre-qualification to its rotavirus vaccine, ROTAVAC 5D.
Pharma Sources Insight 08/2021